Brief: Neurobo Pharmaceuticals Full Data Readout Expected In 2H 2024

MetaVia

18/01/2024 13:12

Jan 18 (Reuters) - Neurobo Pharmaceuticals Inc  NRBO.O :
    * NEUROBO PHARMACEUTICALS REPORTS POSITIVE PRE-CLINICAL
SAFETY
DATA OF DA-1241 IN COMBINATION WITH SITAGLIPTIN AND OPENS
ENROLLMENT FOR PART 2 OF ITS PHASE 2A CLINICAL TRIAL EVALUATING
DA-1241 FOR THE TREATMENT OF MASH
    * NEUROBO PHARMACEUTICALS INC - FULL DATA READOUT EXPECTED
IN
SECOND HALF OF 2024
    * NEUROBO PHARMACEUTICALS INC - OPENED ENROLLMENT FOR PART 2
OF
ITS PHASE 2A CLINICAL TRIAL OF DA-1241 WHEN CO-ADMINISTERED WITH
SITAGLIPTIN
    * NEUROBO PHARMACEUTICALS- ONCE DAILY ORAL ADMINISTRATION IN
RATS
OF SITAGLIPTIN ALONE/ SITAGLIPTIN WITH DA-1241 FOR 13 WEEKS, WAS
WELL TOLERATED

Source text for Eikon:  ID:nPn22RXmna 
Further company coverage:  NRBO.O 

 ((Reuters.Briefs@thomsonreuters.com;))